Piramal Imaging Sa

Bayer Schering Pharma Ag

Massachusetts Institute of Technology

Harvard College

Schering Aktiengesellschaft

Philogen S.p.a.

Bayer Pharma Aktiengesellschaft

Life Molecular Imaging Sa

A. N. Nesmeyanov Institute of Organoelement Compounds, the Russian Academy of Science (ineos Ras)

Institute of the Human Brain, Russian Academy of Science (ihb Ras)

Matthias Friebe

Johannes Platzek

Mathias Berndt

Heribert Schmitt-Willich

Andreas Huth

Detlev Sülzle

Keith Graham

Andreas Schildan

Christina Hultsch

Christoph-Stephan Hilger

Thomas Brumby

Lutz Lehmann

Ludger Dinkelborg

Peter Muschick

Marianne Patt

Norman Koglin

Fabrice Samson

Christoph Smuda

Alan L Davison

Alun G Jones

Cristina Bolzati

Luciano Zardi

Dae Yoon Chi

Niels Böhnke

Byoung Se Lee

Andre Müller

Barbara Carnemolla

Michael Harre

Seung Jun Oh

Laura Borsi

Ashfaq Mahmood

Yuri Belokon

Enrica Balza

Patrizia Castellani

Rainer Braun

Gunnar Garke

Filip Novak

Nikolaevna Raisa Krasikowa

Sang Don Park

Fedorovna Olga Kuznetsova

Matthias Berndt

Olga Fedorovna Kuznetsova

Raisa Nikolaevna Krasikowa

Chi Dae Yoon

L Ist Naz Per La Ricerca Sul Cancro Zardi

Laura Ist Naz Per La Ricerca Sul Cancro Borsi

B Inst Naz Per Ricerca Sul Cancro Carnemolla

P Ist Naz Per La Ricerca Sul Cancro Castellani

Enrica Ist Naz Per La Ricerca Sul Cancro Balza

This invention relates to methods, which provide access to [F-18]fluoropegylated (aryl/heteroaryl vinyl)-phenyl methyl amine derivatives.

Method for production of F-18 labeled amyloid beta ligands

The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.

[F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation

What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.

[F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation

This invention relates to homoglutamic acid derivatives suitable for labeling or already labeled withF orF, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging.

Homoglutamic acid derivatives

This invention relates to novel precursors suitable forF radiolabeling of glutamate derivatives, methods for preparing such compounds and its intermediates, compositions comprising such compounds, kits comprising such compounds or compositions and methods forF radiolabeling of glutamate derivatives wherein the obtainedF radiolabeled glutamate derivatives are suitable for diagnostic imaging by Positron Emission Tomography (PET) of proliferative diseases e.g. tumor in mammals.

Precursors of glutamate derivatives

The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.

Selective targeting of tumor vasculature using antibody molecules

This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.

Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy

The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Growing community of inventors

Berlin, Germany

Matthias Friebe